This program provides awareness of current challenges in the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The emergence of newer therapeutic approaches leads to the creation of new opportunities to improve patient care and establish treatment goals. A greater understanding of new mechanistic actions may directly impact patient QoL. Clinicians, especially among hematologists and advanced care nurses, may lack confidence in their ability to fully treat patients with PNH due to inadequate control of anemia which is often overlooked due to a greater priority in measuring lactate dehydrogenase (LDH). In turn, by increasing awareness of the latest and emerging data surrounding the C3 pathway, its clinically meaningful impact on controlling PNH, and associated impact on efficacy and safety, hematologists and advanced care nurses can become more comfortable integrating new therapies into practice. These agents are likely to have a significant impact and fill an unmet need in the treatment of PNH and ultimately improve patient QoL.